Abstracts tagged "prognostic factors"

Abstract Number: 0489 • ACR Convergence 2023
Prediction of Low Disease Activity in Patients with Psoriatic Arthritis Treated with Secukinumab in Real World – Data from a German Observational Study
Asmir Vodencarevic¹, Jan Brandt-Juergens², Daniel Peterlik¹, Benjamin Gmeiner¹ and Uta Kiltz³, ¹Novartis Pharma GmbH, Nürnberg, Germany, ²rheumatologische Schwerpunktpraxis, Berlin, Germany, ³Rheumazentrum Ruhrgebiet, Herne, Germany
Background/Purpose: Secukinumab (SEC) proved to be an effective treatment for patients with psoriatic arthritis (PsA) in previous randomized clinical trials [1]. There is only limited…
Abstract Number: 1243 • ACR Convergence 2023
Tubulointerstitial Inflammation Is Associated with End-Stage Renal Disease in Pediatric Lupus Nephritis: A Single Center Retrospective Cohort Study
Ryan Mitacek, Qiong Liu, Linda Wagner-Weiner, Shireen Hashmat and Anthony Chang, University of Chicago, Chicago, IL
Background/Purpose: Lupus nephritis (LN) is associated with significant morbidity and mortality. The 2018 International Society of Nephrology/Renal Pathology Society (ISN/RPS) classification criteria and the NIH…
Abstract Number: 2134 • ACR Convergence 2023
Autoantibodies to Joint-related Proteins Predict Remission with High Specificity in New Onset RA
Monica Leu Agelii¹, Outi Sareila², Erik Lönnblom², Kristina Forslind³, Maria Andersson³, Alf Kastbom⁴, Christopher Sjöwall⁵, Lennart Jacobsson⁶, Jan Kihlberg⁷, Rikard Holmdahl², Ingiäld Hafström² and Inger Gjertsson⁸, ¹Gothenburg University, Goteborg, Sweden, ²Karolinska Institutet, Stockholm, Sweden, ³FoU Spenshult, Halmstad, Sweden, ⁴Linköping University, Linköping, Sweden, ⁵Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection/Rheumatology, Linköping University, Linköping, Sweden, ⁶University of Gothenburg, Malmö, Sweden, ⁷Uppsala University, Uppsala, Sweden, ⁸Department of Rheumatology and Inflammation research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
Background/Purpose: One of the major challenges in the management of rheumatoid arthritis (RA) is to determine individual treatment and predict the prognosis. On a group…
Abstract Number: 0554 • ACR Convergence 2023
A Refined Disease Activity Immune Index Informed by Select Immune Mediators That Characterizes Clinical Disease Activity in Systemic Lupus Erythematosus
Melissa Munroe¹, Derek Blankenship², Daniele DeFreese², Adrian Holloway², Mohan Purushothaman², Wade DeJager³, Susan Macwana³, Joel Guthridge³, Stan Kamp³, Nancy Redinger³, Teresa Aberle³, Eliza Chakravarty³, Cristina Arriens⁴, Yanfeng Li⁵, Hu Zeng⁵, Stephanie Dezzutti⁶, Peter Izmirly⁷, Uma Thanarajasingam⁵, Diane L. Kamen⁶, Jill Buyon⁸, Judith James³ and Eldon Jupe², ¹Oklahoma Medical Research Foundation; Progentec Diagnostics, Inc., Oklahoma City, OK, ²Progentec Diagnostics, Inc., Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Oklahoma Medical Research Foundation and University of Oklahoma Health Sciences Center, Department of Arthritis & Clinical Immunology, Oklahoma City, OK, ⁵Mayo Clinic, Rochester, MN, ⁶Medical University of South Carolina, Charleston, SC, ⁷New York University School of Medicine, New York, NY, ⁸NYU Grossman School of Medicine, New York, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease marked by varied disease activity, underscored by complex immune dysregulation, including altered immune mediators and…
Abstract Number: 1268 • ACR Convergence 2023
Clinical Characteristics of Patients with Rheumatoid Arthritis (RA) Who Rate Their Global Assessment of Disease Activity Substantially Lower Than Their Physicians (Negative Discordance) Based on a Large RA Database in Japan: A Rare but Important Subgroup
Tetsuji Sawada¹, Susumu Nishiyama², Shohei Yamashita³, Toshihiro Matsui⁴ and Shigeto Tohma⁵, ¹Tokyo Medical University Hospital, Shinjuku Tokyo, Japan, ²Kurashiki Medical Center, Kurashiki, Japan, ³Tokyo Medical University Hospital, Shinjuku, Japan, ⁴NHO Sagamihara National Hospital, Kanagawa, Japan, ⁵NHO Tokyo National Hospital, Dallas, TX
Background/Purpose: Discordance between patient global assessment (PGA) and physician global assessment (PhGA) regarding the disease activity of rheumatoid arthritis (RA) can be divided into three…
Abstract Number: 2163 • ACR Convergence 2023
Omnipresent Poor Prognostic Factors in Early Rheumatoid Arthritis in the IMPROVED Trial; Is Earlier bDMARD Treatment Escalation for All Necessary?
Joy van der Pol¹, Sytske Anne Bergstra², Thomas Huizinga² and CF Allaart², ¹Leiden University Medical Center, Utrecht, Netherlands, ²Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: The EULAR recommendations for the treatment of RA state, by expert opinion, that if a treatment target is not achieved with the first csDMARD…
Abstract Number: 0618 • ACR Convergence 2023
Incident versus Prevalent Interstitial Lung Disease in Systemic Sclerosis in the EUSTAR Database: Different Disease Phenotypes and Prognosis
liubov Petelytska¹, Arthiha Velauthapillai², Lorenzo Tofani³, Patricia Carreira⁴, Giovanna Cuomo⁵, Eric Hachulla⁶, Ivan Castellvi⁷, Radim Becvar⁸, Alexandra Balbir-Gurman⁹, Paolo Airò¹⁰, Irena Litinsky¹¹, Lesley Ann Saketkoo¹², Madelon Vonk¹³, Jeska de Vries-Bouwstra¹⁴, Anna Maria Hoffmann-Vold¹⁵, marco Matucci Cerinic¹⁶, Oliver Distler¹⁷ and Cosimo Bruni¹⁷, ¹Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ²Department of Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, ³Department of Statistics, Computer Science, Applications, University of Florence, Florence, Italy, ⁴Hospital Universitario 12 de Octubre, Madrid, Spain, ⁵Department of Precision Medicine, “Luigi Vanvitelli” University of Campania, Naples, Italy, ⁶University of Lille, Lille, France, ⁷Rheumatology, Hospital Universitari de la Santa Creu i Sant Pau, Sant Just Desvern, Spain, ⁸Institute of Rheumatology, Prague, Czech Republic, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Praha, Czech Republic, ⁹Rheumatology Institute, Rambam Health Care Campus and Rappaport Faculty of |Medicine, Technion, Haifa, Israel, ¹⁰Spedali Civili di Brescia, Scleroderma UNIT, UOC Reumatologia ed Immunologia Clinica, Piazzale Spedali Civili 1, 25123, Brescia, Italy, ¹¹Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ¹²University Medical Center - Comprehensive Pulmonary Hypertension Center and ILD Clinic Programs // New Orleans Scleroderma and Sarcoidosis Patient Care & Research Centeris, New Orleans, LA, ¹³Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ¹⁴Leiden University Medical Center, Leiden, Netherlands, ¹⁵Oslo University Hospital, Department of Rheumatology, Oslo, Norway, ¹⁶Unit of Immunology, Rheumatology, Allergy and Rare diseases, IRCCS San Raffaele Hospital, Milan, Milan, Italy, ¹⁷Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
Background/Purpose: Although 50% of patients with systemic sclerosis (SSc) present with interstitial lung disease (ILD) at baseline, new onset of ILD can also occur later…
Abstract Number: 1284 • ACR Convergence 2023
Baseline Data’s Role in Predicting All-cause Mortality in Chinese Rheumatoid Arthritis Patients: Findings from the China Registry of Rheumatoid Arthritis (CREDIT) Study
Kangping Huang¹, Mucong Li¹, Chen Yu¹, Nan Jiang¹, Jiuliang zhao¹, Qian Wang¹, Peng Yin², Xinping Tian¹, Mengtao Li¹ and Xiaofeng Zeng¹, ¹Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ²Chinese Center for Disease Control and Prevention, Beijing, China
Background/Purpose: Rheumatoid arthritis (RA) poses significant challenges for patients in China due to prolonged disease duration prior to a definitive diagnosis, resulting in comorbidities and…
Abstract Number: 2174 • ACR Convergence 2023
JAK Inhibitors in Rheumatoid Arthritis-Interstitial Lung Disease. National Multicenter Study of 73 Patients, 55 of Baricitinib
Ana Serrano-Combarro¹, Belén Atienza-Mateo², Jesus Alejandro Valero-Jaimes³, Marta Pastor-Mena⁴, Rafael Benito Melero-Gonzalez⁵, David Castro-Corredor⁶, Maria Martin-Lopez⁷, Santos Castañeda⁸, Jesus Loarce-Martos⁹, Natalia Mena Vazquez¹⁰, Carmen carrasco-Cubero¹¹, Carolina Diez-Morrondo¹², andrea Garcia-Valle¹³, Gema Bonilla¹⁴, Juan Maria Blanco-Madrigal¹⁵, Natividad del Val del Amo¹⁶, Nuria Vegas Revenga¹⁷, Lorena Perez-Albadalejo¹⁸, Rafaela Ortega Castro¹⁹, Deseada Palma-Sanchez²⁰, Ana Maria fernandez-Ortiz²¹, Patricia Lopez-Viejo²², Maria Lopez-Lasanta²³, Marta Garijo Bufort²⁴, Ivette Casafont-Sole²⁵, Olga Maiz-Alonso²⁶, Juan Moreno-Morales²⁷, Ana Urruticoechea²⁸, Carolina Perez-Garcia²⁹, Jose Rosas³⁰, Virginia Ruiz-Esquide³¹, Delia Fernández-Lozano³², Ignacio Brana Abascal³³, Evelin Cecilia Cervantes-Perez³⁴, Julia Fernandez-Melon³⁵, Cristina Fernandez³⁶, Bryan Josue Flores Robles³⁷, Diego Ferrer³⁸ and Ricardo Blanco³⁹, ¹Hospital Universitario Marques de Valdecilla, IDIVAL, Santander, Spain, ²Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³Hospital Bidasoa, Irún, Spain, ⁴Hospital de Jerez de la Frontera, Cádiz, Spain, ⁵CHU Vigo, O Carballino, Spain, ⁶General University Hospital of Ciudad Real, Santa Cruz de Mudela (Ciudad Real), Spain, ⁷Hospital 12 de Octubre, Madrid, Spain, ⁸Hospital Universitario de la Princesa, Madrid, Spain, ⁹Ramón y Cajal University Hospital, Madrid, Spain, ¹⁰IBIMA, Málaga, Spain, ¹¹Department of Rheumatology, Hospital Universitario de Badajoz, Badajoz, Spain, ¹²Division of Rheumatology, Hospital de León, León, Spain, ¹³Division of Rheumatology, Complejo Asistencial Universitario de Palencia, Palencia, Spain, ¹⁴Department of Rheumatology, Hospital Clínico Universitario La Paz, Madrid, Spain, ¹⁵Division of Rheumatology, H. Universitario de Basurto, Bilbao, Spain, ¹⁶Complejo Hospitalario de Navarra, Pamplona, Spain, ¹⁷Hospital Galdakao- Usansolo, Galdakao, Spain, ¹⁸Division of Rheumatology, Hospital Universitario de Jaén, Jaén, Spain, ¹⁹Hospital Reina Sofía, Cordoba, Spain, ²⁰Hospital Rafael Mendez, Lorca, Spain, ²¹CHU Badajoz, Badajoz, Spain, ²²Division of Rheumatology, Hospital Severo Ochoa, Leganéz, Spain, ²³Hospital Universitari Vall d'Hebron, Rheumatology, Barcelona, Spain, ²⁴H. de Sagunto, Valencia, Italy, ²⁵Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ²⁶University Hospital Donostia, San Sebastian, Spain, ²⁷Hospital Universitario Santa Lucia Cartagena, Cartagena, Spain, ²⁸Hospital Can Misses, Ibiza, Spain, ²⁹Hospital del Mar, Barcelona, Spain, ³⁰Hospital Marina Baixa, Alicante, Spain, ³¹Hospital Clinic, Rheumatology, Barcelona, Spain, ³²Hospital de Mérida, Merida, Spain, ³³Division of Rheumatology, Hospital Universitario Central de Asturias, Oviedo, Spain, ³⁴Complexo Hospitalario Universitario de Pontevedra, Pontevedra, Spain, ³⁵Division of Rheumatology, Hospital Universitario Son Espases, Palma de Mallorca, Spain, ³⁶Hospital Universitario San Juan de Alicante, Alicante, Spain, ³⁷Hospital Universitario San Pedro, Logroño, Spain, ³⁸Division of Pneumology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³⁹Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Interstitial lung disease (ILD) is a severe extra-articular manifestation of rheumatoid arthritis (RA). Abatacept and Rituximab are the recommended drugs. JAK inhibitors (JAKi) have…
Abstract Number: 0638 • ACR Convergence 2023
Application of the 2022 European Society of Cardiology (ESC) Risk Assessment Model in Australian and Singaporean Systemic Sclerosis Patients with Newly Diagnosed Pulmonary Arterial Hypertension (PAH)
Zoe Brown¹, Dylan Hansen², Wendy Stevens³, Nava Ferdowsi⁴, laura ross⁵, Alannah Quinlivan⁶, Joanne Sahhar⁷, Gene-Siew Ngian⁷, Diane Apostolopoulos⁷, Jennifer G Walker⁸, Susanna Proudman⁹, Gim Gee Teng¹⁰, Andrea Hsiu Ling Low¹¹, Kathleen Morrisroe¹² and Mandana Nikpour¹³, ¹The University of Melbourne, Armadale, Australia, ²Department of Rheumatology, St Vincent’s Hospital Melbourne, Fitzroy, Australia, ³Department of Rheumatology, St Vincent's Hospital Melbourne, Fitzroy, Australia, ⁴St Vincents Hospital, Kew, Australia, ⁵St. Vincent's Hospital Melbourne, Fitzroy, Australia, ⁶St Vincent's Hospital Melbourne, Highett, Australia, ⁷Monash Health and Monash University, Clayton, Australia, ⁸Royal Adelaide Hospital, Adelaide, Australia, ⁹Royal Adelaide Hospital and University of Adelaide, Adelaide, Australia, ¹⁰Alexandra Hospital, Department of Medicine, Division of Rheumatology, National University Health System, Singapore, Singapore, ¹¹Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore, ¹²The University of Melbourne at St Vincent’s Hospital Melbourne, Fitzroy, Australia, ¹³The University of Melbourne at St. Vincent’s Hospital Melbourne, Departments of Medicine and Rheumatology, Melbourne, Australia
Background/Purpose: Pulmonary arterial hypertension (PAH) patients can be stratified as low, intermediate, or high risk of 1-year mortality based on clinical, biochemical and haemodynamic prognostic…
Abstract Number: 1285 • ACR Convergence 2023
PROMIS Symptom Clusters Predict Disease Activity in the First 6 Months in Newly Diagnosed RA Patients Starting MTX Therapy: Data from the Canadian Early Arthritis Cohort
Susan Bartlett¹, Clifton Bingham², Orit Schieir³, Marie-France Valois⁴, Gilles Boire⁵, Louis Bessette⁶, Janet Pope⁷, Diane Tin⁸, Carter Thorne⁹, Glen Hazlewood¹⁰, Carol Hitchon¹¹, Edward Keystone¹² and Vivian Bykerk¹³, ¹McGill University, Montreal, QC, Canada, ²Johns Hopkins Medicine, Baltimore, MD, ³McGill University, Montréal, QC, Canada, ⁴McGill University, Pointe-Claire, QC, Canada, ⁵Université de Sherbrooke, Sherbrooke, QC, Canada, ⁶Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec City, QC, Canada, ⁷University of Western Ontario, London, ON, Canada, ⁸Newmarket Rheumatology Consultants, Newmarket, ON, Canada, ⁹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹⁰University of Calgary, Calgary, AB, Canada, ¹¹University of Manitoba, Winnipeg, MB, Canada, ¹²Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ¹³Hospital for Special Surgery, New York, NY
Background/Purpose: We have previously shown that PROMIS-29 physical (pain, fatigue) and emotional (depression, anxiety) symptom clusters can be used to identify 4 distinct early RA…
Abstract Number: 2214 • ACR Convergence 2023
Systematic Literature Review and Meta-analysis Informing the Development of 2023 Spondyloarthritis Research and Treatment Network (SPARTAN) Referral Recommendations for Axial Spondyloarthritis
Abhijeet Danve¹, Maureen Dubreuil², Swetha Ann Alexander³, Yuliya afinogenova⁴, Mohamad Bittar⁵, Alyssa Grimshaw⁶, Liana Fraenkel⁷, Michael LaValley⁸, Anand Kumthekar⁹, Jean liew¹⁰, Marina Nighat Magrey¹¹, Vikas Majithia¹², Sali Merjanah¹³, Hillary Norton¹⁴, Jessica A Walsh¹⁵ and Atul Deodhar¹⁶, ¹Yale University School of Medicine, Glastonbury, CT, ²Department of Rheumatology, Boston University School of Medicine, Milton, MA, ³University of Utah Health, Salt Lake City, UT, ⁴Yale, Hamden, CT, ⁵The University of Tennessee Health Science Center, Memphis, TN, ⁶Yale University, New Haven, CT, ⁷Berkshire Health Systems, Lenox, MA, ⁸Boston University School of Public Health, Arlington, MA, ⁹Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, ¹⁰Boston University, Boston, MA, ¹¹Case Western Reserve University, University Hospitals, Cleveland, OH, ¹²Mayo Clinic Florida, Jacksonville, FL, ¹³Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ¹⁴Inspire Santa Fe Rheumatology, Santa Fe, NM, ¹⁵Salt Lake City Veterans Affairs Health and University of Utah Health, Division of Rheumatology, Salt Lake City, UT, ¹⁶Division of Arthritis and Rheumatic Disease, Oregon Health & Science University, Portland, OR
Background/Purpose: Lack of timely referral of suspected axSpA patients to rheumatologists contributes to misdiagnosis, delayed treatment, and poor outcomes. Currently there are no formal guidelines…
Abstract Number: 0643 • ACR Convergence 2023
Progression of Interstitial Lung Disease in Systemic Sclerosis Does Not Predict Further Progression
Anna-Maria Hoffmann-Vold¹, Liubov Petelytska², Havard Fretheim¹, Trond Mogens Aaløkken³, Mike Becker⁴, Hilde Jenssen Bjørkekjær⁵, Cathrine Brunborg⁶, Cosimo Bruni⁷, Christian Clarenbach⁸, Phuong Phuong Diep⁹, Rucsandra Dobrota⁷, Michael Durheim¹⁰, Muriel Elhai¹¹, Thomas Frauenfelder¹², Suzana Jordan⁷, Emily Langballe¹³, Oyvind Midtvedt¹, Carina Mihai⁷, Oyvind Molberg¹⁴ and Oliver Distler⁷, ¹Oslo University Hospital, Oslo, Norway, ²Bogomolets National Medical University, Kyiv, Ukraine, ³Dept of Radiology, Oslo University Hospital, Oslo, Norway, ⁴Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ⁵Department of Rheumatology, Hospital of Southern Norway, Kristiansand & University of Oslo, Institute of Clinical Medicine, Oslo, Norway, ⁶Oslo Centre for Biostatistics and Epidemiology, Research Support Services, Oslo University Hospital - Rikshospitalet, Oslo, Norway, ⁷Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁸Dept of Pulmonology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁹Dept of Respiratory diseases, University Hospital Oslo, Oslo, Norway, ¹⁰Dept of Respiratory diseases, Oslo University Hospital, Oslo, Norway, ¹¹University Hospital zurich, University of Zurich, Zurich, Switzerland, ¹²Dept of Radiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ¹³Universitetet i Oslo, Oslo, Norway, ¹⁴Dept of Rheumatology, University Hospital Oslo, Oslo, Norway
Background/Purpose: In clinical practice, we often wait for progression of interstitial lung disease (ILD) in systemic sclerosis (SSc) to initiate or escalate therapy. Similarly, progressive…
Abstract Number: 1300 • ACR Convergence 2023
Bone Marrow Edema in MRI Is More Associated with Rapid Radiographic Progression Than Clinically Relevant Radiographic Progression
Kou Katayama¹, Takanobu Okubo², Toshikazu Sato¹, Kitaru Tanaka³, Tomoki Kawahata³, Yuichi Makino⁴ and Hiroshi Ito⁵, ¹Department of Orthopedic Surgery, Katayama Orthopedic Rheumatology Clinic, Asahikawa, Japan, ²Department of Radiology, Katayama Orthopedic Rheumatology Clinic, Asahikawa, Japan, ³Division of Metabolism and Biosystemic Science, Gastroenterology, and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Asahikawa, Japan, ⁴Department of Medicine, Division of Rheumatology, Asahikawa Medical University Hospital, Asahikawa, Japan, ⁵Department of orthpedic surgery, Asahikawa Medical University, Asahikawa, Japan
Background/Purpose: Rapid radiographic progression (RRP) is selected as one of the risk factors for difficult- to- treat RA, which needs to be resolved as soon…
Abstract Number: 2224 • ACR Convergence 2023
Difficult to Treat Axial Spondyloarthritis. Predictors of Poor Outcomes
FERNANDO MONTERO¹, Laura Berbel Arcobé², Karen Carpio Astudillo¹, Jose Maria Bellón³ and Xavier Juanola Roura⁴, ¹Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²H.U. Bellvitge, Barcelona, Spain, ³Gregorio Marañón Health Research Institute, Madrid, Spain, ⁴Hospital Universitari de Bellvitge, Barcelona, Spain
Background/Purpose: The term "Difficult-to-Treat" (D2T) defines those patients who remain active despite having undergone various treatments within the established recommendations. This concept is defined by…

« Previous Page
1
…
4
5
6
7
8
…
18
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].